Fig. 5From: Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS studyProportion of patients with ≥ 50% reduction in monthly migraine days from baseline during 12 weeks by sex. OR, odds ratio; CI, confidence interval. aP = 0.011 vs placebo. bP = 0.002 vs placebo. cP < 0.001 vs placeboBack to article page